Korea’s Biotech Roadmap Aims To Bridge Funding Gaps
Executive Summary
South Korea reaffirms its supportive policy stance for the biotech industry with a new long-term roadmap. The plan covers the entire cycle of drug development, including R&D support to tackle the industry’s ‘valley of death’ and creation of a mega fund to help companies enter global markets.
You may also be interested in...
Korea Signals Continued Policy Support For Pharma In 2018
Despite the regime change, South Korea remained generally supportive of the pharma and biotech industry in 2017. With comprehensive long-term plans proposed to nurture these sectors, the government appears poised to pursue its favorable stance towards industry in the coming year.
Korea's Reimbursement Steps Spark Drug Price Cut Concerns
In its first announcement of major health care measures since the Moon Jae-in administration took charge, South Korea unveils steps to hike its national health insurance coverage ratio to levels in advanced countries, raising concerns that this might lead to sharp drug price cuts.
No Korea-Originated New Drugs Approved Domestically In 2023
Notable new drug approvals in South Korea last year included Pfizer’s Tukysa, Genentech’s Columvi and BeiGene’s Tevimbra, but the tally did not include any domestically-originated products. Alzheimer’s disease therapy lecanemab may be on the horizon this year.